logo-loader
Collagen Solutions PLC

Collagen Solutions CEO expects new business to boost full-year revenue, beating market forecasts

Collagen Solutions PLC (LON:COS) CEO Jamal Rushdy tells Proactive Investors the firm expects full-year revenue to beat market forecasts, driven by deals to develop collagen products on behalf of third parties.

Rushdy also says the company is 'anxiously waiting' a CE Mark approval for its product ChondroMimetic, a minimally-invasive surgically placed scaffold that helps to repair knee cartilage.

Quick facts: Collagen Solutions PLC

Price: £0.04

Market: LSE
Market Cap: £16.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Collagen Solutions PLC named herein, including the promotion by the Company of Collagen Solutions PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Collagen Solutions sees clear path to profitability as commercial...

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence talk Proactive London's Andrew Scott through the firm's results for the year ended 31 March 2019. Revenues were up 22% in the year at £4.5mln, while its loss narrowed by just under £500,000 to £1.22mln. The core...

on 11/7/19

2 min read